ofa lawsuit semaglutide Novo Nordisk is suing U.S. telehealth company Hims and Hers, alleging patent infringement over its planned release of a knockoff version of its Wegovy weight loss pill. Hims and Hers is pushing back, Semaglutide Shortage Ends: Compounded Versions

The study also confirmed tirzepatide's safety profile, with no new health concerns identified over three years

Satiety is not just about a full stomach

Peptide clearance depends on: Half-life (short vs long-acting compounds) Route of administration (subcutaneous vs intramuscular) Structural modifications (e.g., PEGylation or DAC binding) Metabolic rate and enzymatic activity Short-acting peptides like GHRP-6, Ipamorelin, and Tesamorelin are typically cleared within 2448 hours

Review proposal: semaglutide for managing overweight and obesity (TA1152)

The injection is subcutaneous, usually into the abdomen, thigh, or upper arm, and is designed for comfort and ease of use

Few generics are in development